8 May 2024 • 11:30-13:00 • Multifunctional room E • Session translated simultaneously PL/EN
Will Europe lose the race for innovation and investment? How does European legislation translate into the development of innovative drugs and new health technologies? Opportunities and risks in reform of EU pharmaceutical legislation and its impact on EU competitiveness in research and investment. The decline of clinical trials and its consequences. How to build a health and industrial policy ecosystem that encompasses all stages of making innovative medicines and technologies available to patients, from investment to pricing and reimbursement policy? Can a combination of science, business and regulatory change influence the future of Europe and its competitiveness with the USA and China – in the area of the Life Science Industry.
Director General, Employers Union of Innovative Pharmaceutical Companies INFARMA
Public Policy Lead Mid-Europe Region, MSD
Member of the European Parliament
Deputy Director, Department of Medicine, Ministry of Health
Director, Department of Drug Policy and Pharmacy, Ministry of Health
You watching archival version of European Economic Congress
What you can do:
Go to the current edition page or Continue browsing
